Stay updated on Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.

Latest updates to the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded a U.S. NIH grant/contract identifier for the study and updated the site revision to v3.6.6, while the previous revision entry v3.6.5 was removed.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedRevision identifier updated from v3.6.4 to v3.6.5, indicating a new version of the document. This metadata update suggests a small update to the page or its supporting materials without changing the visible content.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded Revision: v3.6.4 and removed Revision: v3.6.3 to reflect a newer version of the Study Protocol and SAP document cited on the page.SummaryDifference0.0%

- Check77 days agoChange DetectedThe revision tag on the page changed from v3.6.2 to v3.6.3, signaling a new version of the document. There is no indication of a change to the visible content of the study record.SummaryDifference0.0%

- Check85 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing the previous Revision: v3.6.0, indicating an updated page revision. This reflects a metadata update rather than a change to the study information itself.SummaryDifference0.0%

- Check99 days agoChange DetectedNew navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment status note ('No longer looking for participants'); the Intervention/Treatment label was updated and the revision/version updated from v3.5.5 to v3.6.0.SummaryDifference0.1%

Stay in the know with updates to Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.